Figure 7
Oral administration of hydrogel-encapsulated DMAPT or DMAMCL inhibits DSS-induced colitis. WT mice were orally administered hydrogel-encapsulated DMAPT or DMAMCL daily for 5 days followed by 7 days of DSS treatment. Spleen weights (a) and colon lengths (b) were measured. (c) Representative H&E-stained colons. Scale bar=100 μm. (d) Histological scores determined from H&E-stained colons. (e) Colonic MPO activity was quantified in the distal colon. (f) Colonic mRNA levels of IL1-β, TNFα, and IL-6 were quantified by qRT-PCR and normalized to mRNA levels for the ribosomal protein 36B4. *P<0.05 compared with mice treated with DSS only.
